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Extracellular calcium flow through neuronal voltage-gated CaV2.2
calcium channels converts action potential-encoded information to
the release of pronociceptive neurotransmitters in the dorsal horn
of the spinal cord, culminating in excitation of the postsynaptic
central nociceptive neurons. The CaV2.2 channel is composed of a
pore-forming α1 subunit (CaVα1) that is engaged in protein–protein
interactions with auxiliary α2/δ and β subunits. The high-affinity
CaV2.2α1·CaVβ3 protein–protein interaction is essential for proper
trafficking of CaV2.2 channels to the plasma membrane. Here,
structure-based computational screening led to small molecules
that disrupt the CaV2.2α1·CaVβ3 protein–protein interaction. The
binding mode of these compounds reveals that three substituents
closely mimic the side chains of hot-spot residues located on the
α-helix of CaV2.2α1. Site-directed mutagenesis confirmed the crit-
ical nature of a salt-bridge interaction between the compounds
and CaVβ3 Arg-307. In cells, compounds decreased trafficking of
CaV2.2 channels to the plasma membrane and modulated the func-
tions of the channel. In a rodent neuropathic pain model, the com-
pounds suppressed pain responses. Small-molecule α-helical mimetics
targeting ion channel protein–protein interactions may represent
a strategy for developing nonopioid analgesia and for treatment
of other neurological disorders associated with calcium-channel
trafficking.
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In the central nervous system, voltage-gated calcium channels(CaVs) play important and diverse roles in the synaptic trans-
mission of electrical signals (e.g., neurotransmitter release), in the
integration and modulation of these signals, and in the transduction
of membrane depolarization into intracellular signals (1). To
accomplish these diverse functions, neurons express a variety of
calcium channels that are composed of large heteromeric as-
semblies of pore-forming α1 (CaVα1), auxiliary α2/δ (CaVα2/δ), β
(CaVβ), and γ (CaVγ) subunits (2–8). The auxiliary subunits are
believed to modulate channel properties and assist in trafficking of
the channels to the plasma membrane (9, 10). A recent cryo-electron
microscopy study of the 3D structure of the CaV1.1 voltage-gated
calcium channel [Protein Data Bank (PDB) ID code: 5GJV] re-
veals that the interaction between pore and auxiliary subunits is
driven by protein–protein interactions (11). Small molecules that
disrupt these interactions could provide tools to study them in vivo
and could potentially serve as lead compounds for the develop-
ment of therapeutic agents to treat a range of neurological disorders
associated with CaVs. Specifically, CaV2.2 is a clinically validated
target for the treatment of human chronic pain (12–14), neuropathic
pain (15), and epilepsy (16) and has been implicated in mechanisms
of neuronal excitotoxicity (17).
Among the CaV auxiliary subunits, CaVβ subunits increase the
surface expression of CaV channels and regulate their bio-
physical properties (18, 19). CaVβ subunits are encoded by four
different genes, CaVβ1–4, including multiple splice variants. Their
3D structure reveals the presence of Src homology 3 (SH3) and
guanylate kinase (GK) domains connected by a HOOK region.
One of these structures (PDB ID code: 1VYT) corresponds to
the cocrystal structure of the β3-subunit and the α-interacting do-
main (CaVα1-AID) of CaV channels (20). It shows that CaVα1-AID is
a 25-residue α-helical structure that tightly binds to a well-
defined groove on the GK domain of the β subunit (21–25).
The structure reveals the presence of three subcavities that ac-
commodate the side chains of Tyr-437, Trp-440, and Ile-441, re-
spectively (22). These residues are considered hot spots, amino acids
that are critical to the protein–protein interaction (26–30). Hot spots
are amino acids that contribute at least 1.4 kcal·mol−1 to the Gibbs
free energy of binding (28–32). Small molecules that mimic the
position of hot spots on CaVα or that bind tightly to hot spots on
CaVβ should disrupt the tight CaVα1·CaVβ protein–protein in-
teraction. To date, no small-molecule antagonists of the CaVα1·
CaVβ interaction have been identified.
Disruption of protein–protein interactions with small mole-
cules is generally considered challenging (33) because of the
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typically large binding interfaces (>1,000 Å2) that result in tightly
bound stable complexes. However, there has been a gradual
increase in the number of small-molecule antagonists of
protein–protein interactions over the past decade (34–38). It
has been suggested that these small molecules work by engaging
or mimicking hot spots located at the protein–protein interface.
Protein–protein interactions such as that of the CaVα1·CaVβ
protein–protein interaction are classified as secondary interactions,
given that the interface is composed primarily of an α-helix
binding to a well-defined cavity. In the past, these interactions
have been amenable to disruption with peptides or peptidomi-
metics (34, 39, 40). Several small molecules have been developed
to successfully disrupt secondary interactions such as Bcl-xL·Bak
(41), IL-2·IL-2Rα (42), and MDM2·p53 interactions (43).
To identify small molecules that inhibit the CaVα1·CaVβ pro-
tein–protein interaction, we resorted to structure-based compu-
tational screening of commercial libraries. Top candidates were
purchased and tested for inhibition with fluorescence polariza-
tion (FP) using fluorescently labeled CaVα1-AID. Starting with hit
compound 1 (BTT-3), we prepared several derivatives, which
eventually led to 6 (BTT-266), a small molecule that disrupted
the binding of CaVα1-AID to the CaVβ3 subunit with single-digit
micromolar inhibition constants. The binding mode of 6 revealed
the presence of a salt-bridge interaction between the carboxylate
moiety of the compound and the guanidium ion of Arg-307 on
CaVβ3. To validate this binding mode, we synthesized compounds
lacking a carboxylate and mutated Arg-307 to evaluate its role on
the activity of compound 6. We further validated the predicted
binding mode of 6 through the synthesis of a series of derivatives.
This led to 14 (BTT-369), a derivative with a cell-permeable tetra-
zole moiety instead of the carboxylic group of 6. Patch-clamp ex-
periments explored the effect of 6, 14, and an inactive analog 2
(BTT-245) on the function and trafficking of the CaV2.2 calcium
channel. Finally, 6, 14, and the inactive analog 2 were evaluated in
animal models of neuropathic pain.
Results
Structure-Based Virtual Screening. The structural basis of the
CaVα1·CaVβ interaction was revealed in a cocrystal structure between
CaVβ3 and CaVα1-AID (Fig. 1A) (20). CaVα1-AID is a 25-residue
α-helix that binds to a well-defined groove on the GK domain of
CaVβ3 (Fig. 1B). Previous biophysical studies combined with site-
directed mutagenesis on CaVα1-AID show the presence of three
hot-spot residues (Tyr-437, Trp-440, and Ile-441) (22). The side
chain of these residues is ensconced into three subsites. Small
molecules that bind to the subsites and mimic CaVα1-AID hot spots
are expected to disrupt this interaction. To identify small molecules
that bind to CaVβ at the protein–protein interaction interface, we
resorted to virtual screening, focusing on the large binding cavity
on CaVβ3. SiteMap (44) scoring of the cavity leads to a SiteScore of
1.01, suggesting that the pocket is highly druggable (45). Therefore,
small molecules that bind to this pocket have the potential to exhibit
in vivo efficacy similar to those of Food and Drug Administration-
approved drugs. We stipulated that a small molecule that binds to
this pocket will disrupt the CaVα1·CaVβ3 protein–protein interac-
tion. To that end, a total of 500,000 compounds from the ChemDiv
commercial library were docked to the druggable pocket on CaVβ3
(Fig. 1C). The resulting protein-compound structures were scored and
rank-ordered to select top candidates. The top 500 compounds from
the GoldScore and ChemScore scoring functions were visualized, and
86 compounds were selected for purchase by visual inspection.
Screening Top Candidates. To test for binding of the top-ranking
compounds, we developed an FP assay. In general, the assay consists
of a fluorescently labeled probe, typically a small peptide, and the
target protein of interest. Upon binding to the larger protein, the
labeled peptide experiences decreased motion, which leads to an
increase in light polarization. Small molecules that displace the
peptide lead to a decrease in light polarization. The change in po-
larization can be used to quantify the extent of inhibition. CaVα1·CaVβ
is ideally suited for an FP assay since the α-helix of CaVα1-AID is the
minimum required epitope for binding to CaVβ and the peptide is
substantially smaller than CaVβ. The CaVα1-AID peptide was synthe-
sized and fluorescently labeled at its N terminus. The fluorescently
labeled CaVα1-AID binds to CaVβ3 with a Kd of 21 ± 2 nM (Fig. 1D).
This binding curve was used to select the protein concentration
for titration with the compound. The FP assay was used to screen
the 86 compounds that emerged from the computational screen
at 50 μM. Four compounds inhibited binding of labeled peptide
to CaVβ3 (SI Appendix, Fig. S1A). A follow-up concentration-dependent
study showed that one compound, 1 (BTT-3), inhibited fluo-
rescently labeled CaVα1-AID binding to CaVβ3 with a Ki of 6.7 ±
0.3 μM (SI Appendix, Fig. S1B) with a predicted binding mode
shown in SI Appendix, Fig. S1C.
Design, Synthesis, and Binding Studies of Derivatives. To further
probe the predicted binding mode of 1 (SI Appendix, Fig. S1C)
and to identify compounds with higher affinity, we designed and
synthesized 14 derivatives (Fig. 2A and SI Appendix, Figs. S2–S8).
The binding mode of 1 revealed that the R4 group of the compound
binds to a pocket on CaVβ3 occupied by Tyr-437 on CaVα1. The R4
pocket is a long, narrow binding site that can accommodate an
additional substituent at the para position of the benzene ring. We
introduced a piperazine ring at the para position of the benzene ring at
R4 in compound 3 (BTT-268) and a pyridine in compound 4 (BTT-
267) at the same position. Although 3 did not bind, 4 inhibited the
protein–protein interaction.
In addition to R4, we made modifications at the R2 moiety. The
phenyl group of the R2 substituent of 1 is solvent-exposed, and the
group is engaged in favorable interactions with several hydropho-
bic residues that include Val-192, Met-195, Met-196, and Ala-199
(SI Appendix, Fig. S9). We modified this group to an isopropyl
moiety in compound 5 (BTT-265), which led to complete loss of
binding. This suggests that the R2 aromatic group of 1 is essential
for binding.
We stipulated that the rotatable bonds of the R1 moiety may
lead to unfavorable entropy of binding, especially considering
that this group is likely fixed into the pocket occupied by Ile-441.
We converted the butyric acid to a benzoic acid moiety in
6 (BTT-266), which resulted in a substantial increase in affinity
to a Ki of 1.4 ± 0.1 μM. Unlike several of the compounds that did
not completely inhibit the CaVα1·CaVβ3 protein–protein in-
teraction at high concentrations, likely due to poor solubility,
6 showed complete inhibition (Fig. 2B). Compound 6 possesses a
chiral center at its core pyrazoline ring. Molecular docking of
(R)-6 and (S)-6 resulted in two different binding modes for the
enantiomers as expected (Fig. 2C and SI Appendix, Fig. S10). The
(S)-6 binding mode appears to be the most plausible, considering
the excellent overlap between three of the compound substituents
with three of the most critical hot spots on CaVα1-AID, namely Tyr-437,
Trp-440, and Ile-441 (Fig. 2D and SI Appendix, Fig. S11). The R3 and
R4 substituents of (S)-6 occupy the same position as Tyr-440 and Trp-
437 of CaVα1-AID, respectively. The R1 substituent of (S)-6 that bears
the benzoic acid moiety occupies the same position as the side chain of
Ile-441. Interestingly, just as in compound 1, the carboxylate of 6 is
involved in a salt-bridge interaction with Arg-307 (Fig. 2C andE). Salt-
bridge interactions are commonly found in small-molecule
protein–protein interaction inhibitors. We have previously shown
that disruption of the uPAR·uPA protein–protein interaction by IPR-
803 was completely dependent on a salt bridge (46) that was later
independently confirmed by crystallography (47). To confirm the
importance of the salt bridge, we used the FP assay to test
whether a methyl ester precursor of 6, namely 7 (BTT-269) or 2
(BTT-245), a ketone derivative of 1, binds to CaVβ3. Both 2 and
7 closely resemble 6, but they do not possess the negative charge
of the carboxylate moiety of 6. Both 2 and 7 nearly completely








lost their ability to disrupt the CaVα1·CaVβ3 interaction, confirm-
ing the importance of the salt bridge. These results lend further
credence to the predicted binding mode of (S)-6. Carboxylic acids
are known to reduce cell permeability. A common medicinal chem-
istry strategy to maintain the charge of the carboxylate while im-
proving cell permeability is to replace the carboxylate with a tetrazole
moiety. To that end, we prepared 14 (BTT-369). The compound
possessed a Ki identical to that of 6. Other changes to R1 were made
in compound 11 (BTT-274). The twofold reduction in binding affinity
suggests that the amide bond is optimal at this position.
We modified additional substituents on 6 to further confirm its
binding mode. The importance of a phenyl group at R2 was
established by the introduction of a benzyl moiety at R2 in 9
(BTT-278), which led to compete loss of inhibition. Introduction
of methoxy group at the para position of the benzene group of 6
in 10 (BTT-276) led to a twofold reduction in binding.
Finally, we modified the R3 group of 6 by replacing the methyl
group by a chlorine at the para position in 8 (BTT-280). This
resulted in little change to the binding affinity of the compound.
A methoxy group in compound 12 (BTT-368), on the other hand,
resulted in complex loss of binding. An imidazole phenyl moiety
at R3 in compound 15 (BTT-371) also resulted in complete loss
of binding, consistent with the predicted binding mode of these
compounds showing a constricted binding pocket at R3.
It is worth noting that the inhibition curves for 6 and other
compounds are steeper than usual, suggesting potential aggre-
gation. To rule out the possibility that the inhibition of the
CaVα1·CaVβ3 interaction is due to aggregation, we repeated the
concentration-dependent FP study of 6 using 0.05 and 0.25%
Triton X-100 (SI Appendix, Fig. S12A). We find that even a 25-fold
increase in detergent from 0.01 to 0.25% had no effect on the
inhibition curves of 6; the increase of Triton levels to 0.25%
appears to have slightly improved the potency of the compound.
Next, we used centrifugation to spin down the sample to eliminate
all potential aggregates. As shown in SI Appendix, Fig. S12B, there
was no difference in inhibition of the CaVα1·CaVβ3 interaction by 6
Fig. 1. Computational screening followed by biochemical testing identifies a compound that binds to CaVβ3. (A) 3D structure of CaVα1·CaVβ (PDB ID code:
1VYT). The AID, the GK domain, the SH3 domain, the HOOK domain that links GK and SH3, and the N terminus are shown in violet, green, orange, cyan, and
red ribbon representation, respectively. (B) Stereo close-up view of the CaVα1-AID in complex CaVβ3 (PDB ID code: 1VYT). CaVα1-AID is depicted as a magenta
ribbon, and hot spot residues are shown as capped sticks. CaVβ3 is shown in a solvent-accessible surface area color-coded by hydrophobicity ranging from less
hydrophobic (green) to more hydrophobic (brown). (C) Schematic depicting the workflow that was used for the structure-based computational screening. (D,
Upper) A depiction of the FP assay. (Lower) The plot corresponds to the change in FP as a result of titration of CaVβ3 with increasing concentration of flu-
orescently labeled CaVα1-AID peptide.
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in the presence or absence of spin down. Finally, we tested whether
compound 6 inhibits unrelated tight protein–protein interactions,
which would be expected if the compounds are inhibiting through
aggregation. We used an FP assay that we developed for the tight
single-digit nanomolar-affinity protein–protein interaction between
the TEAD4 transcription factor and its coactivator Yap1. The
compounds showed no inhibition of this interaction (SI Appendix,
Fig. S12C). Collectively, these results suggest that inhibition of the
CaVα1·CaVβ3 interaction by our compounds is not due to aggre-
gation. Steep curves may be more common among compounds
that target single-digit nanomolar-affinity interactions that occur
over a large protein–protein interaction interface, as reported for
ABT-737, a BCl-2 antagonist (48).
Direct Binding Confirmed by Label-Free Microscale Thermophoresis.
To confirm direct binding of 6 to CaVβ3, we resorted to label-free
microscale thermophoresis (MST) (Fig. 2F) (49). The method takes
advantage of a laser-induced temperature gradient. The molecules
migrate along the gradient, and their movement over time is mon-
itored by a fluorescent microscope, resulting in characteristic traces
as shown in SI Appendix, Fig. S13. To obtain a binding affinity,
a concentration-dependent study is performed with a fixed
concentration of protein. If binding occurs, the thermophoretic
signal will change with respect to concentration and is used to
derive a dissociation constant, Kd. Unlabeled proteins have been
successfully used to explore small-molecule binding with MST
(50). The raw data shown in SI Appendix, Fig. S13 were used to
generate a binding curve shown in Fig. 2F. The curves led to a Kd
of 3.6 ± 1.1 μM. The MST binding constant is consistent with the
Ki of 1.4 ± 0.1 μM that was obtained from the FP assay.
Site-Directed Mutagenesis Confirms a Critical Salt Bridge. The
binding mode of 6 reveals that the compound forms a salt-bridge
interaction with Arg-307 through a benzoic acid moiety. The
removal of the charge from the compound, as in methyl ester 7,
led to complete loss of inhibition of the CaVα1·CaVβ3 interaction.
To further confirm the importance of this salt bridge and to establish
the predicted binding mode, we mutated Arg-307 to alanine. The
resulting CaVβ3 Arg-307-Ala mutant binds to CaVα1-AID with a Kd of
240 ± 59 nM (Fig. 2G). The reduction of Kd by nearly 10-fold
suggests that Arg-307 is important for the CaVα1-AID·CaVβ3 pro-
tein–protein interaction and could potentially be considered a hot
spot. We used the CaVβ3 Arg-307-Ala mutant to develop an FP
assay to test whether binding of the mutant protein to CaVα1-AID is
Fig. 2. Design and synthesis of a focused library identifies 6 (BTT-266) that inhibits the CaVα·CaVβ3 protein–protein interaction. (A) Chemical structure of
derivatives that were designed and synthesized based on the structure of 1. (B) The FP assay is used to determine an inhibition constant for 6. (C) Binding
mode of 6 to CaVβ3. This model was generated by molecular docking of the compound to the crystal structure of CaVβ3. The compound is shown as capped
sticks and is color-coded by atom type (cyan, red, and blue correspond to carbon, oxygen, and nitrogen, respectively). CaVβ3 is shown in a solvent-accessible
surface color-coded based on hydrophobicity (green, less hydrophobic; brown, more hydrophobic). (D) The binding mode of 6 superimposed on the binding
mode of CaVα1-AID (PDB ID code: 1VYT) shown in magenta tube rendering. Compound 6 is shown in capped-sticks representation color-coded by atom type.
Hot spots on CaVα1-AID are shown as magenta capped sticks to illustrate the overlap with substituents on 6. (E) A 2D representation of the binding mode of 6
shown in C and D. The schematic shows the compound chemical structure along with the residues that are involved in intermolecular interactions with the
compound. Hydrophobic, positively charged, negatively charged, and polar residues are colored green, blue, red, and cyan, respectively. Solvent-exposed
atoms are shown by gray circles in the background. The salt bridge between Arg-307 and the compound is shown by a pink line. (F) The binding curve that
emerged from the use of MST to establish direct binding of compound 6. Curve-fitting analysis led to a Kd of 3.6 ± 1.1 μM. (G) An FP assay was developed
using the CaVβ3 Arg-307-Ala (R307A) mutant titrated to the CaVα1-AID fluorescently labeled peptide. The binding constant obtained from this analysis is 3.6 ±
1.1 μM. (H) Compound 6 does not inhibit the protein–protein interaction between CaVβ3 Arg-307-Ala as evidenced by a lack of displacement of fluorescently
labeled CaVα1-AID bound to the mutated CaVβ3.








inhibited by compound 6 (Fig. 2G). Interestingly, compound 6 lost
nearly all its affinity to the CaVβ3 Arg-307-Ala mutant, as shown in
Fig. 2H. This loss of affinity was similarly observed in the other
compounds (SI Appendix, Fig. S14). This further confirms the
importance of the salt-bridge interaction and validates the
binding mode of the compound to CaVβ3.
Compound 6 Reduces Trafficking of CaV2.2 to the Plasma Membrane.
Previous studies have shown that CaVα1·CaVβ interaction is re-
sponsible for channel trafficking, and other studies have suggested
that disruption of this interaction may affect the function of the
calcium channel. Here, we use 6 to explore these questions. First,
we determined whether 6 affects the targeting of the CaV2.2α1
subunit to the plasma membrane. We employed a surface bio-
tinylation approach (Fig. 3A). We found that at 50 μM, 6 signifi-
cantly decreased surface presentation of the CaV2.2α1 subunit. To
confirm these results, we resorted to the patch-clamp technique.
We recorded CaV2.2 currents in HEK-CaV2.2 cells pretreated with
10, 25, and 50 μM of 6 for 48 h (Fig. 3B). We found that the
current densities obtained in the cells treated with 50 μM 6 were
significantly decreased compared with group treated with vehicle
(DMSO) (IDMSO = −98.0 ± 12.5 pA/pF, n = 12 vs. I6 = −28.7 ±
5.0 pA/pF, n = 15; P < 0.001) (Fig. 3B). This is consistent with the
surface biotinylation results.
We used 6 to explore whether compounds affected channel func-
tion. Notably, the conductance–voltage (G–V) curves for CaV2.2 were
shifted toward more positive potentials in HEK-CaV2.2 cells pre-
treated with 6 for 48 h (Fig. 3C). The mean half-activation potential
was greater in the cells pretreated with 6 than in the control cells
pretreated with DMSO for 48 h (DMSO: 6.7 ± 0.6 mV, n = 14; 6:
9.4 ± 1.2 mV, n = 14, P < 0.05) (Fig. 3C, Inset). Conversely, acute
application of 50 μM 6 did not affect CaV2.2 currents in either in
HEK-CaV2.2 cells or rat dorsal root ganglion (DRG) neurons (Fig. 3
D and E), indicating that the compound does not inhibit the channel
pore directly. The inactive analog 2, which did not inhibit the CaVα1·
CaVβ3 protein–protein interaction, did not affect the CaV2.2 current
amplitudes in HEK-CaV2.2 cells when it was used acutely or as a
long-term treatment (Fig. 4A).
Compound 14 Modulates the Voltage Dependence of Activation and
Steady-State Inactivation of CaV2.2. When activated by depolariz-
ing pulses to 0 mV from a holding potential of −80 mV, the
densities of CaV2.2 currents were significantly smaller in HEK-
CaV2.2 cells pretreated for 48 h with 50 μM 14 than in cells
treated with 50 μM 2 or DMSO (48 h; 14: −11.1 ± 2.4 pA/pF, n = 12;
2: −79.2 ± 8.2 pA/pF, n = 9; DMSO: −74.8 ± 7.0 pA/pF, n = 15;
P < 0.001) (Fig. 4A). The apparent IC50 for inhibition of CaV2.2
currents by 14 is 31 μM (Fig. 4B).
Since the CaVα1·CaVβ3 protein–protein interaction may
modulate the voltage dependence of activation and steady-state
inactivation of CaV2.2α1, and considering that the values of
CaVα1 half-activation and half-inactivation potentials were more
Fig. 3. Compound 6 decreases the cell-surface presentation of CaV2.2 channels. (A) Western blot analysis of cell-surface biotinylated proteins isolated from
HEK-CaV2.2 cells treated with 6 (BTT-266) (+; n = 10) or with the vehicle control DMSO (−; n = 9) for 48 h. (Upper) A representative blot probed with the
CaV2.2 antibody and the Na
+,K+-ATPase antibody. (Lower) A comparison of the amounts of cell-surface biotinylated CaV2.2 proteins normalized to that of
Na+,K+-ATPase. *P < 0.05. (B) (Upper) Summary data of the current densities recorded in HEK-CaV2.2 cells pretreated for 48 h with the vehicle (DMSO) or
10 μM 6 (n = 9) (Left), 25 μM 6 (n = 6) (Center), or 50 μM 6 (n = 15) (Right). *P < 0.001; ns, not significant. (Lower) Sample traces of the current–voltage relationships
acquired during the voltage ramps from −100 mV to +80 mV in the DMSO (Left) and 6 at 50 μM (Right) groups. Insets show the CaV2.2 currents activated by
depolarizing pulses to 0 mV. (C) Effect of 6 on the voltage dependence of activation of CaV2.2 channels in HEK-CaV2.2 cells pretreated with the vehicle or the
indicated compounds for 48 h. The G–V curves are shown. The Inset shows a comparison of half-activation potentials in DMSO- and 50 μM 6-pretreated HEK-
CaV2.2 cells (48 h). (D and E, Left) Time courses of CaV2.2 currents recorded in an HEK-CaV2.2 cell (D; n = 15) or in a DRG neuron (E, [BaCl2]out = 2 mM; n = 12)
during acute applications of 6 (50 μM). Insets show the superimposed traces of CaV2.2 currents activated by depolarizing pulses to 0 mV in the absence and
presence of 6. (Center) The corresponding current–voltage relationships obtained in the absence and presence of 6. (Right) Summaries of the data. Compound 6
was applied as indicated by the horizontal bars. a, b, and c show the times when the current traces were recorded. ns, not significant.
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negative in CaVα1·CaVβ3-coexpressing cells (51, 52), we explored
whether 14 can modulate the voltage dependence of steady-state
inactivation and/or activation of CaV2.2 in HEK-CaV2.2 cells.
Fig. 4C shows that the CaV2.2 steady-state inactivation curves
were significantly shifted toward more positive potentials in HEK-
CaV2.2 cells pretreated for 48 h with 14 (50 μM, V0.5, inact =
−52.9 ± 1.3 mV, P < 0.05, n = 10) than in the control group
(2; 50 μM, V0.5, inact = −61.6 ± 2.0 mV, n = 10). While analyzing
current–voltage relationships obtained during voltage ramps (Fig. 4D),
we also found that the mean half-activation potential for Cav2.2
channels exhibited a more positive value in HEK-Cav2.2 cells
pretreated for 48 h with 14 (50 μM, V0.5, act = 16.5 ± 1.1 mV, P <
0.001, n = 12) than in the controls (DMSO: V0.5, act = 8.7 ±
1.1 mV, n = 12; 2: 50 μM, V0.5, act = 8.5 ± 1.4 mV, n = 9). These
two findings are consistent with the hypothesis that 14 disrupts
CaVα1·CaVβ3 interactions.
Thus far, we used only long-term pretreatments (48 h) of
HEK-CaV2.2 cells with 6 and 14. Since 14 lacks the negatively
charged carboxylate group in the R1 substituent of 6, which is
replaced with an isosteric tetrazole moiety, 14 is more membrane
permeable than 6. The data presented above suggested that 14may
disrupt the intracellular CaVα1·CaVβ3 protein–protein interaction
in live cells. Therefore, we then asked whether acute short-term
treatments with 14 in patch-clamped HEK-Cav2.2 cells could
modulate the half-activation potential for Cav2.2 channels. No
significant change in the mean half-activation voltage value was
observed in patch-clamped HEK-Cav2.2 cells acutely treated
with DMSO (before treatment: V0.5, act = 9.1 ± 1.6 mV; 5 min
under DMSO: V0.5, act = 6.8 ± 3.3 mV, n = 3, P > 0.05) (Fig. 4E,
Left). Conversely, a 5-min incubation with 50 μM 14 was suffi-
cient to significantly shift the G–V curves of Cav2.2 toward more
positive potentials (before treatment: V0.5, act = 6.4 ± 1.9 mV;
5 min under 14: V0.5, act = 11.4 ± 1.7 mV, n = 7, P < 0.01) (Fig.
4E, Right), indicating that the Cav2.2 channel requires stronger
depolarization to be activated in the presence of 14.
Pharmacokinetic Properties of Compound 14. Voltage-dependence
of activation and steady-state inactivation experiments in HEK-
Cav2.2 revealed that compound 14 appears to be more potent
than 6 or 2. These observations suggest that 14 may be more
efficacious in vivo than 6 and 2. Before testing 14 in nociceptive
and neuropathic pain using in vivo assays, we sought to understand
the pharmacokinetic properties of the compound in the mouse.
For i.v. administration, 14 was formulated as a solution at a final
dose of 1 mg/kg. Plasma concentrations at various time points were
determined using the LC-MS/MS technique (SI Appendix, Fig.
S15). The elimination half-life of 14 was 0.29 h. The amount of time
that the maximum concentration of the drug was present in plasma
(Tmax) was 0.083 h, and the peak plasma concentration (Cmax) that
Fig. 4. Compound 14 (BTT-369) reduces the current density and modulates the voltage-dependence of activation and steady-state inactivation of CaV2.2. (A)
The CaV2.2 current densities in HEK-CaV2.2 cells pretreated for 48 h with DMSO (n = 15), 14 (n = 12), or 2 (n = 9). (Left) the superimposed raw sample traces of
CaV2.2 currents acquired during the 20-ms depolarizing pulses in HEK-CaV2.2 cells pretreated with the indicated compounds for 48 h. (Right) Summary of the
data. ***P < 0.001. (B) The concentration–effect curve for 14. HEK-CaV2.2 cells were pretreated with various concentrations of compound 14 for 48 h.
CaV2.2 currents were acquired during 20-ms depolarizing pulses, and the current densities were calculated as a ratio of the peak current amplitude and each
cell capacitance (0.1 μM, n = 6; 1 μM, n = 7; 10 μM, n = 8; 50 μM, n = 12). The line is the fit of the data to the four-parameter logistic function. The apparent IC50
value is 31 μM. The same datasets for 50 μM 14 (BTT369) were used in A and B. (C) Effect of 2 (BTT-245) and 14 on the voltage dependence of the steady-state
inactivation of CaV2.2 channels. The Inset shows two superimposed traces acquired during the steady-state inactivation protocol shown below the plot. HEK-
CaV2.2 cells were pretreated with the indicated compounds for 48 h. *P < 0.05. (D) Effects of 2 and 14 on the voltage dependence of the activation of
CaV2.2 channels in HEK-CaV2.2 cells pretreated with the vehicle or the indicated compounds for 48 h. (Left) The average current–voltage relationships ac-
quired during voltage ramps for each test group. (Right) The average G–V curves for each treatment group. The gray vertical lines are error bars indicating
SEM. (E) Acute effects of DMSO and 14 on the voltage dependence of the activation of CaV2.2 channels in HEK-CaV2.2 cells. (Left) Average G–V curves before
and after 5-min incubation with DMSO (P > 0.05). (Right) Average G–V curves before and after 5-min incubation with 14 (P < 0.01). The gray vertical lines are
error bars indicating SEM. ns, not significant.








the drug achieved was 181.36 ng/mL. The area under the curve
(AUC0-t) concentration was 57.99 ng·mL
−1·h−1.
For oral gavage administration, 14 was formulated as a solution
at a final dose of 10 mg/kg. Plasma concentrations at various time
points were again determined using the LC-MS/MS technique
(SI Appendix, Fig. S15). The elimination half-life of 14 was 1.99 h.
The Tmax in plasma was 1 h, and the Cmax was 164.7 ng/mL. The
AUC 0-t concentration was 635.555 ng·mL−1·h−1. Taken together,
these observations indicate that 14 has a significant lifetime in vivo and
may exhibit notable therapeutic potential. Thus, there is a structure–
activity relationship, 14 > 6 > 2, in the chemical series, which
points to potential druggability of the series and the potential to
identify an optimal lead compound as well as the pharmaco-
logical validation and therapeutic potential.
Effects of Compound 6 on Acute Thermal Nociception in the Rat. A
model of behavioral sensitivity using thermal stimulus was used
to determine the acute analgesic properties of the candidate small
molecules. Thermal stimulation serves to activate high-threshold
primary afferent sensory fibers in the hind paw glabrous skin. These
axons carry action potential discharges to the dorsal horn of the
spinal cord to activate secondary nociceptive neurons which con-
tribute to a behavioral response of paw withdrawal from the aversive
stimulus. Systemic administration of 6 failed to elicit changes in the
response latency at 1 or 10 mg/kg (Fig. 5A).
Neuropathic Pain Is Attenuated by Treatment with Compounds 6 and
14 but Not Compound 2. We next examined the effects of mor-
phine and compounds 2 and 6 on established chronic nociceptive
behavior in a model of neuropathic pain, tibial nerve injury
(TNI), 28 d after surgery (Fig. 5B) (53). TNI induces prolonged
chronic behavioral hypersensitivity to mechanical stimuli which
lasts for several months and is generally insensitive to opioids
such as morphine (53, 54). Before exposure to the compound, all
injured animals exhibited pronounced mechanical allodynia (33.1 ±
5.9 mN; n = 8–10) in response to von Frey hair stimulation of the
injured hind paw, compared with presurgery levels, which averaged
68.7 ± 3.7 mN (n = 8–10) (Fig. 5C). Pronounced attenuation of
tactile hypersensitivity was observed at 1 h but not at 4 h after
systemic administration of 6 (10 mg/kg, i.p.; 62.2 ± 3.1 mN; n = 16).
The 6 dosing levels of 1 mg/kg and 0.1 mg/kg failed to alter behavior
at 1 or 4 h. In contrast, systemic administration of morphine
(5 mg/kg) and 2 (10 mg/kg, i.p.) was ineffective in reducing hy-
persensitivity, with levels averaging 32 ± 2.6 mN (n = 8) (Fig. 5C).
That the paw-withdrawal threshold (PWT) returned to baseline by
4 h in 6-injected rats is consistent with the turnover of drug over
this period and is a limitation of this drug candidate. PWTs were
increased significantly at both 1 and 24 h postinjection in rats ex-
posed to 14 (0.1 mg/kg) 28 d after TNI compared with rats injected
with 6 or vehicle control (Fig. 5D).
Discussion
The neuronal CaV2.2 voltage-gated Ca
2+ channel is implicated in
mediating neurotransmitter release in nociceptive neurons.
CaV2.2 channels are large (>400 kDa) heteromeric assemblies
composed of pore-forming α subunits and auxiliary α2/δ and β
subunits (2–8). The auxiliary subunits are believed to modulate
the properties and assist in trafficking of the channels to the plasma
Fig. 5. Compounds 6 and 14, but not 2, reverse mechanical hypersensitivity in the TNI model of neuropathic pain. (A) Bar graph of paw withdrawal latency
(in seconds) of rats (n = 6 per group) demonstrating a lack of analgesic effect for 2 or 6. (B) Diagram of the sural, tibial, and common peroneal terminal nerve
branches of the sciatic nerve and their dorsal root origins. Neuropathic pain was induced by ligation of the tibial nerve, and 2–4 mm of the nerve distal to the
ligation was removed. (C) PWT (in milli-Newtons, mN) in response to von Frey stimulation to the paw ipsilateral to injury following a single i.p. administration
of vehicle, morphine (5 mg/kg), 2, or 6 (10 mg/kg, n = 8) at 4 wk after TNI. The ability of 6 (green striped bar) to reverse TNI-induced mechanical hypersensitivity
was significantly different from that of 2 (solid gray bar) and morphine (black striped bar). *P < 0.05 versus 2 and morphine treatment in TNI rodents (mean ± SE;
n = 8, repeated measures ANOVA with Tukey’s post hoc test). BL, baseline. (D) At 4 wk, a single bolus injection of 14 (0.1 mg/kg) significantly reversed mechanical
hypersensitivity at both 1 and 24 h post dosing. For comparison, reversal of mechanical hypersensitivity by 6 (10 mg/kg) was limited to 1 h. Data are shown as
mean ± SE; n = 8; *P < 0.05 versus 6 and vehicle-treated TNI rodents; repeated-measures ANOVA with Tukey’s post hoc test.
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membrane (9, 10). The transmembrane α2/δ subunit has recently
received renewed interest for being the target of the anticonvulsant
drugs gabapentin (Neurontin) and pregabalin (Lyrica), two moder-
ately effective treatments for clinical neuropathic pain (15, 55).
There is clear evidence showing dysregulation of Ca2+ homeostasis
in many neurological diseases, and studies have demonstrated
that Ca2+ channels are a clinically validated target for the treat-
ment of human chronic pain (12–14) and neuropathic pain (15)
and have been implicated in mechanisms of neuronal excitotoxicity
(17). Most existing drug-discovery efforts targeting calcium channels
have concentrated on the α pore-forming subunits. Protein–protein
interactions between the pore-forming and auxiliary subunits, par-
ticularly the CaVα·CaVβ interaction, have been largely ignored.
Here, we report the discovery of a small molecule that mod-
ulates the CaVα1·CaVβ3 protein–protein interaction of CaVs. We
followed a simple approach that consisted first of docking more
than 500,000 commercially available compounds to the large
pocket at the CaVα·CaVβ3 interface. We visually inspected the
top 500 candidates. Testing of 86 compounds led to 6, which
inhibited the CaVα1·CaVβ3 interaction with a Ki of 1.4 ± 0.1 μM.
Using label-free MST, we confirmed that the compound binds di-
rectly to CaVβ3 and obtained a Kd that was nearly identical to the Ki
from the FP assay. Interestingly, the binding mode of 6 reveals the
presence of a salt-bridge interaction between its benzoic acid moiety
and Arg-307. To confirm the presence of a salt bridge, we tested a
methyl ester derivative of 6, namely 7, as well as a ketone derivative
of 1, namely 2, both of which lacked a charged carboxylate. These
compounds showed a complete loss of inhibition. To further es-
tablish the critical nature of the salt bridge, we mutated Arg-307 to
alanine. We found that 6 completely lost its ability to inhibit the
CaVα1·CaVβ3 interaction in the absence of Arg-307, further confirming
the existence of the critical salt-bridge interaction. The importance of
this salt bridge was further confirmed by the synthesis of 14, a de-
rivative of 6 that possesses a tetrazole moiety instead of carboxylic
acid. The compound exhibited inhibition potency similar to that of 6.
We explored whether the compounds affected calcium-channel
trafficking and function. Previous studies have shown that the in-
teraction with CaVβ is critical for CaV2.2α1 subunit trafficking to
the plasma membrane. We demonstrated that pretreatment of
HEK-CaV2.2 cells with 6 decreased the cell-surface presentation of
CaV2.2α1 proteins. Using patch-clamp studies, we also found that
the compound significantly attenuated channel density at the cell
membrane. Longer treatment time was necessary due to the slow
kinetics of internalization and degradation of CaV2.2 channels
containing the α2δ subunit (56). Collectively, these results confirm
previous studies that the CaVα1·CaVβ interaction is responsible for
channel trafficking. Subsequently, we explored whether the com-
pounds affected cation currents through the channel during an
acute application to exclude a direct effect on the CaV2.2α1 sub-
unit. Patch-clamp analyses revealed that 6 had no acute effect on the
amplitude of Ba2+ currents through the channel. This is reasonable,
considering the latest cryo-electron microscopy structure of CaV1.1
(PDB ID code: 5GJV). Using this structure, we constructed a
homology model of CaV2.2 (SI Appendix, Fig. S16). The model,
which closely resembles that of CaV1.1, shows that the CaVα1·CaVβ
interaction is located outside the channel pore. Hence, disruption
of the CaVα1·Cavβ interaction may not affect cation flow through
the channel.
We also demonstrated that 6 and 14 may modulate the voltage
dependence of CaV2.2 activation. It is well established that the
interaction of CaVβ3 and CaVα1 results in a shift of the half-
maximum voltage of activation for CaV2.2 to more negative
potentials (51, 52). A more negative half-activation potential for
CaV2.2 means that the channel can be activated at more mod-
erate membrane-depolarizing voltages. Conversely, disruption of
the CaVα1·CaVβ protein–protein interaction is expected to shift
the half-activation potential for CaV2.2 toward a more positive
voltage, making it harder for the CaV2.2 channel to be activated
at the moderate depolarizing voltages. Consistently, we found that
14, a membrane-permeable disruptor of the CaVα1·CaVβ protein–
protein interaction, significantly shifted the G–V curves of CaV2.2
toward the positive potentials. The rightward shift of the mean half-
activation potential was most pronounced after a 48-h pretreatment
with 14. However, even following a brief 5-min treatment in patch-
clamped HEK-CaV2.2 cells, the compound was capable of signif-
icantly shifting the G–V curves for CaV2.2 toward more positive
potentials (although in a lesser degree than observed after 48-h
pretreatments). Thus, these data indicate that stronger depolar-
izations are needed to activate CaV2.2 in the presence of 14.
N-type voltage-gated calcium channels (CaV2.2), largely lo-
calized to primary afferent terminals in laminae 1 and 2 of the
dorsal horn, play an important role in pain signaling by con-
tributing to the release of neurotransmitters such as glutamate,
substance P, and calcitonin gene-related peptide (CGRP). De-
velopment of a highly efficacious, nonaddicting analgesic with a
good side-effects profile has been challenging. Clinically ap-
proved blockers of this ion channel to date are encumbered by
numerous off-target effects and exhibit narrow therapeutic win-
dows. Novel small-molecule compounds that are nonaddictive
and alter pain behavior following injury are sought for treatment
of both subacute and chronic pain conditions. We tested whether
6 had an effect on rodent behavior in a neuropathic pain model.
We found that 6 given systemically reversed TNI-hypersensitivity
for 1 h but not 4 h, while the same dose of 2, which did not inhibit
the in vitro CaVα1·CaVβ interaction, had no effect. Similar behav-
ioral effects were observed for 14 for up to 24 h, which is suggestive
of sustained pain relief. These observed effects may be due in part to
a possible pharmacologic block of presynaptic neurotransmitter re-
lease of neuropeptides or changes in the excitability of nociceptive
neurons present in animals with chronic pain conditions. More-
over, this effect may be attributed to a state-dependent affinity
and enhanced high-frequency activation patterns in pain syndromes.
That 6 was unable to alter the behavioral responses to acute thermal
nociception may be attributed to lower-frequency firing patterns
associated with normal nociception (57).
In sum, we identified small molecules that inhibit the protein–
protein interaction between pore and auxiliary subunits of a voltage-
gated ion channel. The compounds are α-helical mimetics. It is likely
that another, similar protein–protein interaction exists in other
ion channels that can be targeted with small molecules. The pro-
found in vivo efficacy of 14 at a dose of 0.1 mg/kg suggests that this
compound offers the potential to develop new treatments for
various neurological conditions associated with aberrant trafficking
and function of calcium channels.
Materials and Methods
Virtual Screening. The crystal structure for CaVβ3 was obtained from the
Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data-
bank (PDB ID code: 1VYT) (58). Structures were imported into SYBYL 8.0, a
molecular modeling suite from Tripos, Inc., for predocking preparation. All
binding partners, ions, and water molecules were removed. Hydrogen atoms
were added, and the protonation states on polar residues were optimized
with Reduce (version 3.03) (59). Structures were then loaded into Auto-
DockTools (60) for further processing. Further details about the docking and
scoring of compounds are provided in SI Appendix.
Protein Expression and Purification. The plasmid of the pET28a-CaV2.2β3
subunit was transformed into a competent Escherichia coli BL21(DE3) strain.
The culture was grown in LB medium at 37 °C to an OD600 of ∼0.6 and then
was induced with 0.5 mM isopropyl β-d-1-thiogalactopyranoside at 16 °C for
16 h. Cells were collected by centrifugation and lysed by microfluidizer in
lysis buffer (phosphate buffer, pH 7.6, 2 mM DTT). The His-CaVβ3 protein was
purified at 4 °C using Ni-IMAC chromatography (His-Trap HP; GE Healthcare)
and was eluted with 500 mM imidazole in lysis buffer with a gradient
method. After the fractions consisting of His-CaVβ3 were combined and con-
centrated, the protein was further purified using size-exclusion chromatog-
raphy (Superdex 200 prep grade; GE Healthcare) in PBS with 2 mM DTT.








FP and MST Analysis. FP was used in a competition format to test compounds
for inhibition of the CaVα·CaVβ3 protein–protein interaction. A fluorescently
labeled peptide that contains the region of CaVα that binds to CaVβ3 was
synthesized. The fluorescent fluorescein-AID peptide was found to bind to
CaVβ3 with a Kd of 21 ± 2 nM. The high affinity of the CaVβ3 probe suggests
that introduction of the fluorescent label to the peptide had no impact on
its binding affinity, which is close to the value that Minor and coworkers (22)
measured using isothermal titration calorimetry. MST analysis was carried
out to confirm direct binding of small molecules to CaVβ3. Further details
about the experimental setup are provided in SI Appendix.
HEK-CaV2.2 Cell Culture. HEK293 cells stably expressing rat N-type CaV2.2α1B,
rat CaVβ3, and rat α2δ-1 were obtained from Diane Lipscombe (Brown Uni-
versity, Providence, RI) (61). Cells were grown in DMEM supplemented with
10% FBS, 50 U penicillin, 50 μg/mL streptomycin, 5 μg/mL blasticidin, 5 μg/mL
hygromycin, and 25 μg/mL zeocin at 37 °C in a humidified atmosphere of
95% air and 5% CO2. For patch-clamp experiments, HEK-CaV2.2 cells were
plated on glass coverslips and were cultured for 24–48 h.
DRG Neuron Isolation. All animal procedures were performed in accordance
with NIH guidelines and were approved by the Indiana University School of
Medicine Institutional Animal Care and Use Committee. Young adult Spra-
gue–Dawley rats were anesthetized (3% isoflurane) and then decapitated.
The spinal column was removed and cut open, and DRGs were harvested
from the lumbar L4–L6 vertebral levels. The ganglia were incubated in
DMEM containing collagenase (1 mg/mL; Worthington; LS04194) and pro-
tease (1 mg/mL; Worthington; LS02104) for 30–60 min, and DRG neurons
were dissociated by triturating in DMEM supplemented with 10% FBS. The
isolated DRG neurons were plated on glass coverslips coated with Growth
Factor Reduced Matrigel (Thermo Fisher Scientific) and were cultured in
Eagle’s minimum essential medium (Invitrogen) supplemented with 0.2%
BSA and 20 ng/mL NGF-2.5S (BD Biosciences) overnight at 37 °C in a water-
jacketed 5% CO2 incubator for the patch-clamp experiments.
Cell-Surface Protein Biotinylation and Western Blotting. Cell-surface protein
biotinylation and Western blotting were performed as previously described
(62). Briefly, HEK-CaV2.2 cells were treated with 6 (BTT-266) or the vehicle
(DMSO) for 48 h. The surface proteins were biotinylated with 5 mM biotin-X-
NHS (EMD Millipore) in PBS for 30 min at 4 °C. After biotinylation, cells were
quenched and washed with PBS containing 100 mM glycine. Then, cells were
lysed in ice-cold RIPA buffer containing the Halt protease inhibitor mixture
(Thermo Fisher Scientific). The lysate was cleared by centrifugation, the
preabsorbed avidin-agarose beads were added, and the resulting suspension
was rotated for 30 min at 4 °C. The avidin-agarose beads were spun down and
then washed three times with the complete lysis buffer. Proteins were eluted
from the beads by incubation with SDS gel loading buffer supplemented with
1mMDTT for 10min at 70 °C. The eluted proteins were separated using 10% SDS-
PAGE, transferred onto PVDF (Immun-Blot; Bio-Rad), and probed with the anti-
CaV2.2-α1B antibody from Alomone Labs (1:1,000 dilution; catalog no. AC002) and
the Na+,K
+-ATPase antibody (1:1,000 dilution; catalog no. 3010; Cell Signaling).
Whole-Cell Patch-Clamp Recordings in HEK-CaV2.2 Cells and DRG Neurons. The
whole-cell patch-clamp technique was used to record CaV2.2 currents in HEK-
CaV2.2 cells and rat DRG neurons as described elsewhere (63). Details of the
experimental procedures used to carry out the patch-clamp recordings
reported in this work are provided in SI Appendix.
Animals. Pathogen-free, adult, female Sprague–Dawley rats (weight at testing
150–200 g) (Harlan–Sprague–Dawley) were housed in a climate-controlled
room on a 12-h light/dark cycle and were allowed to have food and water
ad libitum. All procedures were approved by the Indiana University Animal Care
and Use Committee and conformed to the Guide for the Care and Use of
Laboratory Animals (64) for the use of laboratory animals. All behavioral
experiments were conducted by experimenters blinded to the treatment
conditions and small-molecule candidate identity. The experiments were
replicated a minimum of two times with independent cohorts of animals.
Drug Delivery. For in vivo studies, small-molecule candidates 2, 6, and 14
were freshly prepared using saline (0.9%) on the day of the experiment.
Morphine sulfate salt (Sigma-Aldrich) was freshly prepared on the day of the
experiment in saline. All drugs were dissolved in 1 mL solution and admin-
istered by i.p. injection 1 h before all behavioral assays.
TNI. TNI was performed to model nerve injury-induced neuropathic pain as
described previously (53, 65). Using isoflurane anesthesia (4% induction and
2% maintenance), we isolated the right sciatic nerve under aseptic surgical
conditions by blunt dissection of the femoral biceps muscle, and the tibial
nerve was tightly ligated with 5–0 silk and transected distal to the ligation.
An additional 2–3 mm of the distal nerve stump was removed to prevent
reinnervation by the proximal nerve. The overlying muscle and skin was then
sutured in two separate layers. Sham-injured animals were subjected to all
preceding procedures with the exception of ligation and transection. All ani-
mals were returned to the housing facility and allowed to survive for 28 d.
Assessment of Tactile Hypersensitivity. Mechanical stimuli were applied with
seven filaments, each differing in the bending force delivered (10, 20, 40, 60,
80, 100, and 120 mN) and fitted with a flat tip and fixed diameter of 0.2 mm.
The filaments were tested in the order of ascending force, with each filament
delivered for 1 s. The withdrawal threshold stimulus was sequentially
based on ascending force. A Hill equation was fitted to the function based
on the percentage of specific responses to six stimulations to elicit a 50%
withdrawal rate.
Foot Withdrawal to Thermal Stimulus. To evaluate the PWT to thermal stim-
ulation, we used the Hargreaves’ plantar test apparatus (Ugo Basile) (66).
Measurements of the withdrawal latency of the paw began after the rats
were habituated to the testing environment (infrared setting = 70). The mea-
surements were repeated four times at 5-min intervals; the initial pair of mea-
surements was not used. The averages of the three remaining pairs of
measurements were employed as data.
Synthesis. The synthesis route that was used to prepare compounds in this
work and the structural characterization of the compounds are provided in
SI Appendix.
Statistical Analysis. Differences between means were compared by Student
t tests. The biotinylation data were analyzed using an unpaired Student t test.
The electrophysiological data were analyzed using an unpaired Student t test
(Figs. 3 B and C and 4B) or a paired Student t test (Figs. 3D and 4A). Behavioral
threshold values were statistically analyzed, and the significance of differ-
ences between the average of at least two preinjection tests and the mean
obtained for each postinjection test was analyzed. In all tests, baseline data
were obtained for the TNI-injured groups before drug or vehicle administration
and were compared with the baseline values by repeated-measures ANOVA
followed by the post hoc Tukey’s multiple-comparison test. A P value less than
0.05 was considered to indicate statistical significance between treatment and
nontreatment groups.
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